Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Amicus Therapeutics (FOLD) Enterprise Value (2016 - 2025)

Amicus Therapeutics' Enterprise Value history spans 16 years, with the latest figure at -$293.5 million for Q4 2025.

  • For the quarter ending Q4 2025, Enterprise Value fell 17.44% year-over-year to -$293.5 million, compared with a TTM value of -$293.5 million through Dec 2025, down 17.44%, and an annual FY2025 reading of -$293.5 million, down 17.44% over the prior year.
  • Enterprise Value for Q4 2025 was -$293.5 million at Amicus Therapeutics, down from -$263.8 million in the prior quarter.
  • The five-year high for Enterprise Value was -$231.0 million in Q2 2025, with the low at -$557.0 million in Q3 2021.
  • Average Enterprise Value over 5 years is -$321.2 million, with a median of -$283.2 million recorded in 2023.
  • Year-over-year, Enterprise Value decreased 23.73% in 2021 and then skyrocketed 39.15% in 2022.
  • Tracing FOLD's Enterprise Value over 5 years: stood at -$482.5 million in 2021, then skyrocketed by 39.15% to -$293.6 million in 2022, then increased by 2.52% to -$286.2 million in 2023, then increased by 12.67% to -$249.9 million in 2024, then fell by 17.44% to -$293.5 million in 2025.
  • Per Business Quant, the three most recent readings for FOLD's Enterprise Value are -$293.5 million (Q4 2025), -$263.8 million (Q3 2025), and -$231.0 million (Q2 2025).